Skip to content

Effectiveness of Chai-shi-Tui-Re (CHASE) granules for influenza A: a randomized controlled trial

A randomized, double-blind, placebo controlled trial for Chai-shi-Tui-Re (CHASE) granules for influenza A

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002866
Enrollment
Unknown
Registered
2019-12-23
Start date
2019-12-23
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza A

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Defined according to influenza A diagnostic criteria; 2. TCM syndrome differentiation is wind-heat invading defensive qi or heat-toxicity attacking lung; 3. Onset within 48 hours; 4. Temperature equal or more then 38.0? within 24 hours; 5. Complete blood count shows normal or lower white blood cell count; 6. Aged 18 to 65 years; 7. Patients signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Chest imaging shows that there is a tracheobronchitis, lung infection or active lung tuberculosis; 2. Those with a history of lung cancer, pneumoconiosis, lung abscess, chronic obstructive pulmonary disease and pulmonary heart diseases; 3. Patients with severe primary diseases such as cardiovascular, renal, liver, hematopoiesis, brain, digestive system and psychiatric and malignant tumors; 4. Those who injected influenza vaccination in the past 12 months; 5. Those who have used antivirals, antipyretics, analgesics or traditional Chinese medicine in the past 24 hours; 6. Those who are using systemic glucocorticoids or immunosuppressants; 7. Pregnancy or breast-feeding women; 8. Allergic constitution or those who are allergic to multiple drugs.

Design outcomes

Primary

MeasureTime frame
Defervescence time;

Secondary

MeasureTime frame
Defervescence rate;Utilization rate of analgesic-antipyretic;Incidence of flu complications;symptom score;Negative rate of viral nucleic acid;

Countries

China

Contacts

Public ContactLin Lin
drlinlin620@163.com+86 13903002015

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026